Etg Zamosc Sp. z o.o.

Zamosc 28 trials 18 recruiting

28 Registered trials

18 Currently recruiting

Organisation

Etg Zamosc Sp. z o.o.

Location

Zamosc, Poland

Identifier

ORG-100051968

Address

Ul. Spadek 41, 22-400, Poland

Departments

ETG Zamosc
ETG Zamość Poradnie Specjalistyczne
ETG Zamość Sp
N/A
NA
Site Name: ETG Zamosc/ Ul. Gęsia 3, 22-400 Zamość
TBC

Clinical trials at this site (28)

Search interface

A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending

2025-521037-86-00 Immune system diseases 5
A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti… Pending

2025-521038-27-00 Immune system diseases 5
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending

2025-522471-28-00 psoriatic arthritis (PsA) 5
A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight without type 2 diabetes. Recruiting

2025-523104-71-00 Obesity or Overweight Without Type 2 Diabetes 5 2026-05-08
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting

2024-518296-56-00 Crohn’s Disease 5 2025-09-29
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obe… Recruiting

2024-520209-38-00 Obesity or Overweight 5 2025-09-19
LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study Recruiting

2025-522338-30-00 Ulcerative Colitis 4 2026-03-31
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Recruiting

2025-522674-36-00 Metabolic Dysfunction-Associated Steatotic Liver Diseas 5 2026-03-24
An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting

2025-521036-11-00 Immune system disseases 5 2026-03-23
An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting

2025-521035-37-00 Immune system diseases 5 2026-03-02
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting

2025-521382-27-00 Moderately to Severely Active Crohn's Disease 10 2025-12-04
Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting

2025-521381-10-00 Moderately to Severely Active Ulcerative Colitis 5 2025-12-03
A Study to Assess the Efficacy, Safety, and what the body does to RO7837195 in Participants with Moderately to Severely Active Ulcerative Co… Recruiting

2025-520690-39-00 Moderately to Severely Active Ulcerative Colitis (UC) 4 2025-11-04
A clinical trial to evaluate efficacy and safety of Xeomin® injections for preventing chronic migraine Recruiting

2024-515682-34-00 Chronic migraine 5 2025-10-06
A clinical trial to evaluate efficacy and safety of Xeomin® injections for preventing episodic migraine Recruiting

2024-515715-22-00 Episodic migraine 5 2025-10-06
A randomized, phase 3 multicenter study to confirm the clinical efficacy of linaprazan glurate compared to lansoprazole in participants with… Recruiting

2024-518714-31-00 Erosive esophagitis (EE) due to gastroesophageal reflux 5 2025-10-03
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn’s Disease and Obesity or Overweight:… Recruiting

2024-520210-21-00 Crohn’s Disease 5 2025-09-19
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn’s Disease (CD) Recruiting

2024-518914-18-00 Moderate to Severely Active Ulcerative Colitis & Modera 4 2025-08-27
A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination wi… Recruiting

2024-519945-31-00 Type 1 Diabetes 5 2025-08-21
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients with… Recruiting

2023-510369-92-00 Mixed Dyslipidemia 4 2025-01-28
A Study to Compare Different Doses of RO7795081 with a Placebo or Semaglutide in People with Type 2 Diabetes Ended

2024-520322-11-00 Type 2 Diabetes Mellitus (T2D) 4 2025-09-29
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Psoriatic arthritis 5 2025-03-25
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended

2023-508636-61-00 Crohn’s Disease 5 2024-10-24